Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Carcinoma, Transitional Cell × erdafitinib × Clear all

Status

Sponsor Class

Study Type

Interventional 2 Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

atezolizumab 4 avelumab 3 erdafitinib 1 enfortumab vedotin 1 darolutamide 1 Surgical Procedures, Operative 1 Radiotherapy 1 Nivolumab 1 Mitomycin 1 Magnetic Resonance Spectroscopy 1 Immunotherapy 1 Histocompatibility Testing 1 High-Throughput Nucleotide Sequencing 1 Gemcitabine 1 Drug Therapy 1 Defecation 1 Cytological Techniques 1 Cystoscopy 1 Cisplatin 1 Biomarkers 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05052372 2022-12-22

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

xCures

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡